Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Innova Captab Ltd

INNOVACAP:NSI

Innova Captab Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)787.85
  • Today's Change10.25 / 1.32%
  • Shares traded21.18k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 01 2024 13:52 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Innova Captab Limited is an integrated pharmaceutical company. The Company is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It has presence across the pharmaceuticals value chain, including research and development, manufacturing, drug distribution and marketing and exports. Its business includes Contract Development and Manufacturing (CDMO) business, Domestic Branded Generics, and International Branded Generics product business. Its CDMO business provides research, product development and manufacturing services. Its Branded Generics business consists of the development, manufacture and distribution of generic formulation products, which are marketed and distributed in India under its own brand names through online and offline channels. Its generic drug products are also available online through various e-commerce pharmacy sites. It has developed a diversified branded generics product portfolio including Tablets, dry syrups, capsules, and others.

  • Revenue in INR (TTM)11.42bn
  • Net income in INR1.06bn
  • Incorporated2005
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Indoco Remedies Ltd17.73bn320.40m28.60bn5.93k93.032.6320.981.613.343.34175.26118.230.81941.524.512,989,727.001.366.881.999.8568.3465.591.666.930.81421.710.433914.028.9113.41-30.78--34.5437.97
Dishman Carbogen Amcis Ltd24.16bn-2.48bn30.54bn1.13k----176.821.26-15.81-15.81154.06--------21,344,260.00---0.3986---0.488879.3073.83-10.27-1.54---0.7216----8.414.91-414.93---0.3175--
RPG Life Sciences Limited6.00bn923.20m41.48bn1.27k44.93--37.556.9255.8255.82362.60--------4,721,969.00--16.07--21.7768.4262.9915.3911.99--220.43--29.2713.5012.0129.6051.9828.6046.14
Solara Active Pharma Sciences Ltd12.22bn-5.36bn42.96bn2.16k--2.57--3.52-137.13-137.13320.29301.630.47311.772.695,667,023.00-20.76-2.44-36.40-3.8438.7041.16-43.89-4.490.448-1.300.4355---10.73-1.45-2,458.12---4.81--
Jeena Sikho Lifecare Ltd-100.00bn-100.00bn43.37bn1.23k--137.18----------12.72------------------------0.8228--0.2681--43.84--77.37------
Morepen Laboratories Ltd17.45bn1.18bn43.77bn1.62k34.57--29.252.512.312.3134.26--------10,749,300.00--7.90--13.3437.8633.346.775.49--33.34--0.0019.2517.08148.6327.2247.03--
Gufic BioSciences Ltd8.14bn863.69m43.97bn1.45k50.41--42.505.408.708.7081.95--------5,624,707.00--11.46--19.2152.3945.7910.6010.46--8.09--1.3116.8018.128.0731.4653.8314.87
Aarti Drugs Ltd23.80bn1.52bn44.19bn1.06k29.133.4621.491.8616.6216.62259.74139.960.99543.163.4322,364,630.006.379.739.6215.7834.6022.236.408.251.016.830.3159---6.9010.133.0713.8224.96--
Innova Captab Ltd11.42bn1.06bn44.50bn--32.82--35.813.9023.6923.69236.62------------10.82--18.3833.3825.189.308.04--8.89----16.7224.9038.8436.55104.14--
SeQuent Scientific Ltd14.27bn54.87m45.44bn1.20k853.41--58.503.190.21370.213757.18--------11,939,190.00--1.09--1.7645.3841.970.99021.18--0.9009--35.06-3.605.6870.40--6.96--
Hikal Ltd18.03bn677.82m46.93bn2.06k69.28--24.772.605.495.49145.97--------8,749,879.00--5.07--7.5153.0646.783.765.86--2.45--12.19-11.792.34-11.20-7.559.720.00
Supriya Lifescience Ltd6.25bn1.58bn50.18bn448.0031.915.5428.718.0319.5419.5477.55112.560.67372.016.5613,950,510.0016.9819.0818.3824.0466.8157.1225.2024.714.05111.460.0062.8823.7415.4732.5624.7583.79--
Aarti Pharmalabs Ltd19.68bn2.28bn57.96bn1.63k25.413.1218.882.9525.1625.16217.12204.880.77331.624.5912,095,750.008.96--11.86--45.56--11.59--0.961117.120.1723---4.76--12.10------
Unichem Laboratories Ltd17.28bn-605.50m58.55bn3.19k----112.073.39-8.59-8.59245.15--------5,410,587.00---1.67---2.0362.0056.18-3.50-3.99--0.1401----26.947.6465.15---35.00--
Data as of Nov 01 2024. Currency figures normalised to Innova Captab Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

13.24%Per cent of shares held by top holders
HolderShares% Held
Kotak Mahindra Asset Management Co. Ltd.as of 30 Sep 20242.21m3.86%
Canara Robeco Asset Management Co. Ltd.as of 30 Sep 20242.09m3.66%
Invesco Asset Management (India) Pvt Ltd.as of 30 Sep 20241.50m2.61%
SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 31 Aug 20241.05m1.83%
Bandhan AMC Ltd.as of 30 Sep 2024320.93k0.56%
Edelweiss Asset Management Ltd.as of 30 Sep 2024313.78k0.55%
WhiteOak Capital Asset Management Ltd.as of 30 Sep 202482.31k0.14%
SSgA Funds Management, Inc.as of 03 Oct 202412.79k0.02%
More ▼
Data from 30 Jun 2024 - 15 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.